We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
More federal regulators are knocking on Theranos’ door, keen on getting answers to questions about staff qualifications and improper review of patient test results. Read More